

118TH CONGRESS
2D SESSION

S. 4839

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the Office of National Drug Control Policy with respect to the World Anti-Doping Agency, and for other purposes.

IN THE SENATE OF THE UNITED STATES

JULY 30, 2024

Mrs. BLACKBURN (for herself and Mr. VAN HOLLEN) introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and Transportation

A BILL

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the Office of National Drug Control Policy with respect to the World Anti-Doping Agency, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Restoring Confidence
5 in the World Anti-Doping Agency Act of 2024”.

1 **SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY**
2 **WITH RESPECT TO THE WORLD ANTI-DOPING**
3 **AGENCY.**

4 Section 701 of the Office of National Drug Control
5 Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is
6 amended—

7 (1) in subsection (a)—

8 (A) by amending paragraph (1) to read as
9 follows:

10 “(1) UNITED STATES OLYMPIC AND
11 PARALYMPIC COMMITTEE.—The term ‘United States
12 Olympic and Paralympic Committee’ means the or-
13 ganization established by chapter 2205 of title 36,
14 United States Code.”;

15 (B) in paragraph (3), by striking “(36
16 U.S.C. 22501(b)(1))” and inserting “(36
17 U.S.C. 220501(b)(1))”;

18 (C) by redesignating paragraphs (1) and
19 (3) as paragraphs (4) and (1), respectively, and
20 moving the paragraphs so as to appear in nu-
21 meric order; and

22 (D) by inserting after paragraph (2) the
23 following:

24 “(3) INDEPENDENT ATHLETE.—The term
25 ‘independent athlete’ means an Olympic or

1 Paralympic athlete who does not serve, in any capac-
2 ity—

3 “(A) on the International Olympic Com-
4 mittee;

5 “(B) on the International Paralympic
6 Committee;

7 “(C) at an international sports federation
8 recognized by the International Olympic Com-
9 mittee or the International Paralympic Com-
10 mittee;

11 “(D) on the United States Olympic and
12 Paralympic Committee; or

13 “(E) at the World Anti-Doping Agency.”;

14 (2) in subsection (b)—

15 (A) by striking “United States Olympic
16 Committee” each place it appears and inserting
17 “United States Olympic and Paralympic Com-
18 mittee”;

19 (B) in paragraph (5), by striking the pe-
20 riod at the end and inserting “; and”; and

21 (C) by adding at the end the following:

22 “(6) carry out responsibilities with respect to
23 the World Anti-Doping Agency, as described in sub-
24 section (d).”; and

25 (3) by adding at the end the following:

1 “(d) AUTHORITY WITH RESPECT TO THE WORLD
2 ANTI-DOPING AGENCY.—

3 “(1) IN GENERAL.—The Office of National
4 Drug Control Policy, in consultation with the United
5 States Anti-Doping Agency, the United States Olym-
6 pic and Paralympic Committee, and the Team USA
7 Athletes’ Commission, shall—

8 “(A) use all available tools to ensure
9 that—

10 “(i) the World Anti-Doping Agency
11 has a credible and independent governance
12 model that provides for fair representation
13 of the United States;

14 “(ii) the World Anti-Doping Agency
15 fully implements all governance reforms,
16 including a proper conflict-of-interest pol-
17 icy for all members of the Executive Com-
18 mittee, the Foundation Board, and all rel-
19 evant expert advisory groups, standing
20 committees, permanent special committees,
21 and working groups of the World Anti-
22 Doping Agency; and

23 “(iii) independent athletes from the
24 United States and other democratic coun-
25 tries, or representatives of such athletes,

1 have decision-making roles on the Execu-
2 tive Committee and the Foundation Board,
3 and in all relevant expert advisory groups,
4 standing committees, permanent special
5 committees, and working groups, of the
6 World Anti-Doping Agency;

7 “(B) demonstrate leadership within the
8 global community;

9 “(C) have strict standards that work to-
10 ward countering doping in every form, including
11 by countering systemic fraud through doping
12 involving—

13 “(i) governmental law enforcement,
14 intelligence, or anti-doping institutions;

15 “(ii) sporting organizations; or

16 “(iii) athlete support personnel; and

17 “(D) work collaboratively with democratic
18 countries.

19 “(2) DETERMINATION.—

20 “(A) IN GENERAL.—Not later than 90
21 days after the date of the enactment of this
22 subsection, the Office of National Drug Control
23 Policy, in consultation with the United States
24 Anti-Doping Agency, the United States Olympic
25 and Paralympic Committee, and the Team USA

1 Athletes' Commission, shall make a determina-
2 tion as to whether the World Anti-Doping
3 Agency—

4 “(i) has a credible and independent
5 governance model that provides for fair
6 representation of the United States;

7 “(ii) fully implements all governance
8 reforms, including a proper conflict-of-in-
9 terest policy described in paragraph
10 (1)(A)(ii); and

11 “(iii) allows independent athletes from
12 the United States and other democratic
13 countries, or representatives of such ath-
14 letes, to have decision-making roles on the
15 Executive Committee and the Foundation
16 Board, and in all relevant expert advisory
17 groups, standing committees, permanent
18 special committees, and working groups, of
19 the World Anti-Doping Agency.

20 “(B) ACCOUNTABILITY.—In the case of a
21 determination under subparagraph (A) that the
22 World Anti-Doping Agency does not have such
23 a governance model, has not fully implemented
24 such governance reforms, or has not allowed de-
25 cision-making roles described in clause (iii) of

1 that subparagraph, the Office of National Drug
2 Control Policy, in consultation with the United
3 States Anti-Doping Agency, the United States
4 Olympic and Paralympic Committee, and the
5 Team USA Athletes' Commission, shall—

6 “(i) use all available tools to ensure
7 that the United States has fair representa-
8 tion in the World Anti-Doping Agency, in-
9 cluding—

10 “(I) on the Executive Committee;

11 “(II) on the Foundation Board;

12 and

13 “(III) in all relevant expert advi-
14 sory groups, standing committees,
15 permanent special committees, and
16 working groups of the World Anti-
17 Doping Agency; and

18 “(ii) not later than 180 days after the
19 date on which the determination under
20 subparagraph (A) is made, issue a report
21 that describes the barriers to participation
22 and fair representation of the United
23 States on the Executive Committee, the
24 Foundation Board, and all relevant expert
25 advisory groups, standing committees, per-

1 manent special committees, and working
2 groups of the World Anti-Doping Agency.

3 “(3) VOLUNTARY NONPAYMENT OF DUES.—

4 “(A) IN GENERAL.—In the case of a deter-
5 mination under paragraph (2)(A) that the
6 World Anti-Doping Agency does not have a gov-
7 ernance model that provides for fair representa-
8 tion of the United States, has not fully imple-
9 mented governance reforms, or has not allowed
10 decision-making roles described in clause (iii) of
11 that subparagraph, the Office of National Drug
12 Control Policy, in consultation with the appro-
13 priate committees of Congress, may voluntarily
14 withhold up to the full amount of membership
15 dues to the World Anti-Doping Agency.

16 “(B) APPROPRIATE COMMITTEES OF CON-
17 GRESS DEFINED.—In this paragraph, the term
18 ‘appropriate committees of Congress’ means—

19 “(i) the Subcommittee on Consumer
20 Protection, Product Safety, and Data Se-
21 curity of the Committee on Commerce,
22 Science, and Transportation of the Senate
23 (or a successor subcommittee);

24 “(ii) the Subcommittee on Financial
25 Services and General Government of the

1 Committee on Appropriations of the Sen-
2 ate (or a successor subcommittee);

3 “(iii) the Subcommittee on Oversight
4 and Investigations of the Committee on
5 Energy and Commerce of the House of
6 Representatives (or a successor sub-
7 committee); and

8 “(iv) the Subcommittee on Financial
9 Services and General Government of the
10 Committee on Appropriations of the House
11 of Representatives (or a successor sub-
12 committee).

13 “(4) SPENDING PLAN.—Not later than 30 days
14 before the Office of National Drug Control Policy
15 obligates funds to the World Anti-Doping Agency,
16 the Office of National Drug Control Policy shall sub-
17 mit to the Committee on Appropriations of the Sen-
18 ate and the Committee on Appropriations of the
19 House of Representatives a spending plan and expla-
20 nation of proposed uses of such funds.”.

○